Rein Therapeutics enrolls first patients in Phase 2 IPF trial
Rein Therapeutics has confirmed that eight patients have been enrolled in the RENEW Phase 2 clinical trial evaluating LTI-03 in idiopathic pulmonary fibrosis (IPF), with two further enrolments anticipated within days of the announcement. The Austin, Texas-based company began recruiting in March 2026 and is steadily expanding its global site footprint.
Active clinical sites are currently operating in the United States, Australia, and Poland. Rein said the United Kingdom and Germany are expected to come online in the near term, with further countries to follow as the company works to fill a target enrolment of approximately 120 patients. The randomised, placebo-controlled study will compare two dose levels of LTI-03 against placebo, with forced vital capacity (FVC) — a standard measure of lung function — as the primary efficacy endpoint.
The candidate
LTI-03 is an inhaled synthetic peptide derived from Caveolin-1 biology, a pathway the company describes as a key regulator of fibrotic signalling. Rein positions the drug as a dual-acting agent: one that may slow progressive lung scarring while simultaneously preserving alveolar progenitor cells needed for tissue repair. The candidate holds Orphan Drug Designation in the United States. Rein's chief executive, Brian Windsor, said the pace of enrolment and site expansion reflects strong execution by its clinical teams, though no interim safety or efficacy data were disclosed alongside the update.
Market context and competitive landscape
IPF is a progressive and ultimately fatal lung disease with a median survival of three to five years from diagnosis and a global patient population estimated in the hundreds of thousands. The approved standard of care — nintedanib (Boehringer Ingelheim) and pirfenidone (originally Shionogi, now widely genericised) — slows FVC decline but does not halt or reverse fibrosis, leaving substantial unmet need. That gap has attracted a sizeable cohort of late-stage challengers; among them are programmes targeting the TGF-β pathway, lysophosphatidic acid receptor 1 (LPA1), and connective tissue growth factor, as well as several inhaled approaches similar in delivery concept to LTI-03.
The FVC endpoint Rein has chosen is well-established with regulators: both pirfenidone and nintedanib secured approval partly on the basis of FVC preservation, giving the RENEW trial a clear precedent for regulatory interpretation. The FDA's 2022 draft guidance on drug development for IPF reinforced FVC decline as an acceptable primary endpoint for accelerated or traditional approval pathways, which should ease dialogue as Rein moves toward a potential end-of-Phase 2 meeting.
With only eight patients enrolled against a 120-patient target, RENEW is at an early stage, and investors will be watching enrolment velocity and the timing of any interim data readout as the key near-term catalysts for the NASDAQ-listed stock.